SEC calls out little TherapeuticsMD for its insider contacts with analysts to boost share price, then halt rout
Back in May 2017, following an FDA rejection, TherapeuticsMD saw its share price plummet to the lowest levels in two years. The little Florida biotech eventually found its way back to the good side of regulators, scoring a curious OK a year later for its therapy preventing vaginal pain during sex. But the SEC is now accusing it of selectively disclosing nonpublic information in attempts to manipulate its stock.
In two instances in June and July of 2017, TherapeuticsMD allegedly violated the Regulation Fair Disclosure rule by sharing material information with certain sell-side analysts and not the public, resulting in a more favorable stock move than otherwise would be expected.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.